The STRIDE regimen (Imfinzi plus Imjudo) demonstrated a 24% reduction in the risk of death compared to sorafenib in unresectable hepatocellular carcinoma (HCC).
AstraZeneca's Imfinzi plus Imjudo (STRIDE regimen) demonstrated a significant overall survival benefit in patients with unresectable hepatocellular carcinoma (HCC).
The combination of Imfinzi and Imjudo has demonstrated unprecedented overall survival (OS) in advanced liver cancer, with one in five patients surviving five years.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.